FDG-PET staging of head and neck cancer - Can improved imaging lead to improved treatment?

Journal of the National Cancer Institute

Volumn 100, Issue 10, 2008, Pages 688-689

  Schwartz, David L ^a   Macapinlac, Homer A ^a   Weber, Randal S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ASPIRATION BIOPSY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; EDITORIAL; HEAD AND NECK CANCER; HUMAN; LYMPH NODE DISSECTION; LYMPHADENOPATHY; NECK DISSECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; HEAD AND NECK TUMOR; LYMPH NODE; LYMPH NODE METASTASIS; METHODOLOGY; NECK; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PREDICTION AND FORECASTING; RADIOGRAPHY; SCINTISCANNING;

FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; NECK; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 44449125146     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn149     Document Type: Editorial

References (18)

1. Centers for Medicare & Medicaid Services. U. S. Department of Health and Human Services. http://www.cms.hhs.gov/mcd/viewnca.asp?nca_id=92&basket= . Accessed April 17, 2008.
2. 18F- fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst. 2008;100(10):712-720.
3. Righi PD, Kopecky KK, Caldemeyer KS, Ball VA, Weisberger EC, Radpour S. Comparison of ultrasound-fine needle aspiration and computed tomography in patients undergoing elective neck dissection. Head Neck. 1997;19(7):604-610.
4. Takes RP, Righi P, Meeuwis CA, et al. The value of ultrasound with ultrasound-guided fine-needle aspiration biopsy compared to computed tomography in the detection of regional metastases in the clinically negative neck. Int J Radiat Oncol Biol Phys. 1998;40(5):1027-1032.
5. Vermeersch H, Loose D, Ham H, Otte A, Van de Wiele C. Nuclear medicine imaging for the assessment of primary and recurrent head and neck carcinoma using routinely available tracers. Eur J Nucl Med Mol Imaging. 2003;30(12):1689-1700.
6. Gregoire V. Is there any future in radiotherapy planning without the use of PET: unraveling the myth. Radiother Oncol. 2004;73(3):261-263.
7. Ha PK, Hdeib A, Goldenberg D, et al. The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2006;132(1):12-16.
8. Connell CA, Corry J, Milner AD, et al. Clinical impact of, prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck. 2007;29(11):986-995.
9. Hojgaard L, Specht L. PET/CT in head and neck cancer. Eur J Nucl Med Mol Imaging. 2007;34(9):1329-1333.
10. Kovacs AF, Dobert N, Gaa J, Menzel C, Bitter K. Positron emission tomography in combination with sentinel node biopsy reduces the rate of elective neck dissections in the treatment of oral and oropharyngeal cancer. J Clin Oncol. 2004;22(19):3973-3980.
11. Ng SH, Yen TC, Chang JT, et al. Prospective study of [18F] fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. J Clin Oncol. 2006;24(27):4371-4376.
12. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med. 2005;46(6):983-995.
13. A randomized phase 3 trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab (C225) (followed by surgery for selected patients) for stage 3 and 4 head and neck carcinomas. Radiation Therapy Oncology Group RTOG 0522. http://www.rtog.org/members/protocols/0522/0522.pdf. April 17, 2008.
14. Hillner BE, Liu D, Coleman RE, et al. The National Oncologic PET Registry (NOPR):design and analysis plan. J Nucl Med. 2007;48(11):1901-1908.
15. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359(9315):1388-1393.
16. Reed CE, Harpole DH, Posther KE, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003;126(6):1943-1951.
17. Herder GJ, Kramer H, Hoekstra OS, et al. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol. 2006;24(12):1800-1806.
18. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.